Biodiversity Literature Repository

Submit to community
Liberated Data
Published April 2, 2021 | Version v1
Journal article Open

Target animal safety evaluation of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for cats

Authors/Creators

  • 1. Boehringer-Ingelheim Animal Health, 3239 Satellite Blvd, Duluth, 30096 GA, USA (until 2020)
  • 2. Boehringer-Ingelheim Animal Health, 1730 Olympic Drive, Athens, 30601 GA, USA
  • 3. Boehringer-Ingelheim Animal Health, 29 Avenue Tony Garnier, 69007 Lyon, France

Description

Gupta, Aradhana, Baker, Christine, Wang, Hailun, Targa, Norba, Pfefferkorn, Anthony, Tielemans, Eric (2021): Target animal safety evaluation of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for cats. Parasite (Paris, France) 28 (18): 1-9, DOI: 10.1051/parasite/2021015, URL: https://doi.org/10.1051/parasite/2021015

Files

source.pdf

Files (239.5 kB)

Name Size
md5:c11b965e30c91264c7c901a01f949cb8
239.5 kB Preview Download

Linked records

Additional details

Identifiers

LSID
urn:lsid:plazi.org:pub:C11B965EFFC91264FFC9FFA0FF94FFB8

Related works

Cites
Publication: 10.1101/605170 (DOI)

References

  • 1. Baker CF, Tielemans E, Pollmeier MG, McCall JW, McCall SD, Irwin J, Chester ST, Carithers DS, Rosentel JK. 2014. Efficacy of a single dose of a novel topical combination product containing eprinomectin to prevent heartworm infection in cats. Veterinary Parasitology, 202, 49-53.
  • 2. Beugnet F, Bourdeau P, Chalvet-Monfray K, Cozma V, Farkas R, Guillot J, Halos L, Joachim A, Losson B, Miro G, Otranto D, Renaud M, Rinaldi L. 2014. Parasites of domestic owned cats in Europe: co-infestations and risk factors. Parasites & Vectors, 7, 291.
  • 3. Caffrey CR. 2007. Chemotherapy of schistosomiasis: present and future. Current Opinion in Chemical Biology, 11(4), 433-439.
  • 4. Drag M, Saik J, Harriman J, Larsen D. 2014. Safety evaluation of orally administered afoxolaner in 8-week-old dogs. Veterinary Parasitology, 201(3-4), 198-203.
  • 5. EMA. CVMP assessment report for BROADLINE (EMEA/V/C/ 002700/0000): International non-proprietary name: Fipronil / (S)- methoprene/praziquantel / eprinomectin, 2013, EMA/674955/2013. Veterinary Medicines Division.
  • 6. Greenberg RM. 2005. Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature. Parasitology, 131(Suppl.), S97-S108.
  • 7. Hong ST. 2018. Albendazole and Praziquantel: review and safety monitoring in Korea. Infection and Chemotherapy, 50(1), 1-10.
  • 8. Jacquot V, Buellet P, Letendre L, Tong W, Li H, Tielemans E. 2021. Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. Parasite, 28, 19.
  • 9. Kvaternick V, Kellermann M, Knaus M, Rehbein S, Rosentel J. 2014. Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. Veterinary Parasitology, 202, 2-9.
  • 10. Lankas GR, Gordon LR. 1989. Toxicology, in Ivermectin and Abamectin, Campbell WC, Editor. Springer-Verlag: New York, Berlin, Heidelberg, London, Paris, Tokyo. p. 89-112.
  • 11. Merola VM, Eubig PA. 2012. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of p-glycoprotein in dogs and cats. Veterinary Clinics of North America Small Animal Practice, 42(2), 313.
  • 12. Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C. 2009. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Neglected Tropical Diseases, 3, 3-7.
  • 13. Mahende MK, Huber E, Kourany-Lefoll E, Ali A, Hayward B, Bezuidenhout D, Bagchus W, Kabanywanyi AM. 2019. Comparative palatability of orally disintegrating tablets (ODTs) of praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: a randomized, single-blind, crossover study. bioRxiv. https://doi.org/10.1101/605170.
  • 14. Pitt SR, Langholff W, Eagleson JS, Rehbein S. 1997. The efficacy of eprinomectin against induced infections of immature (fourth larval stage) and adult parasites in cattle. Veterinary Parasitology, 73, 119-128.
  • 15. Rehbein S, Capari B, Duscher G, Keidane D, Kirkova Z, Petkevicius S, Rapti D, Wagner A, Wagner T, Chester ST, Rosentel J, Tielemans E, Visser M, Winter R, Kley K, Knaus M. 2014. Efficacy against nematode and cestode infections and safety of a novel topical fipronil, (S)-methoprene, eprinomectin and praziquantel combination product in domestic cats under field conditions in Europe. Veterinary Parasitology, 202(1-2), 10-17.
  • 16. Shoop WL, Hartline EJ, Gould BR, Waddell ME, McDowell RG, Kinney JB, Lahm GP, Long JK, Xu M, Wagerle T, Jones GS, Dietrich RF, Cordova D, Schroeder ME, Rhoades DF, Benner EA, Confalone PN. 2014. Discovery and mode of action of afoxolaner, a new isoxazoline parasiticide for dogs. Veterinary Parasitology, 201, 179-189.
  • 17. Tielemans E, Prullage J, Otsuki T, Cheesman T, Selmes F, Pfefferkorn A, Wang H. 2021. Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions. Parasite, 28, 22.
  • 18. VICH Guideline GL 43. 2008. Target animal safety - pharmaceuticals: Target animal safety for veterinary pharmaceutical products.
  • 19. Walther FM, Fisara P, Roepke RKA. 2018. Safety of topical administration of fluralaner plus moxidectin concurrently with praziquantel in cats. Parasites & Vectors, 11, 597.